Vertex Pharmaceuticals (VRTX) Upgraded to “Sell” at BidaskClub

Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Wednesday.

Several other equities analysts have also recently commented on the stock. Bank of America restated a “buy” rating and set a $180.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, January 23rd. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, January 21st. JPMorgan Chase & Co. restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, January 9th. Oppenheimer boosted their price target on shares of Vertex Pharmaceuticals from $175.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, January 4th. Finally, Deutsche Bank assumed coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $175.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and twenty-five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $175.89.

Vertex Pharmaceuticals (NASDAQ:VRTX) traded up $2.97 during trading on Wednesday, hitting $169.21. 1,500,000 shares of the stock traded hands, compared to its average volume of 1,580,000. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. Vertex Pharmaceuticals has a fifty-two week low of $82.66 and a fifty-two week high of $169.30. The stock has a market cap of $42,790.00, a PE ratio of 216.94, a P/E/G ratio of 1.97 and a beta of 1.58.

In other news, EVP Stuart A. Arbuckle sold 8,969 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $169.00, for a total transaction of $1,515,761.00. Following the completion of the transaction, the executive vice president now owns 46,262 shares of the company’s stock, valued at $7,818,278. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Paul M. Silva sold 1,289 shares of the company’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $152.31, for a total transaction of $196,327.59. Following the transaction, the senior vice president now directly owns 17,923 shares of the company’s stock, valued at approximately $2,729,852.13. The disclosure for this sale can be found here. In the last three months, insiders have sold 564,736 shares of company stock valued at $84,672,410. Company insiders own 1.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Achmea Investment Management B.V. raised its position in shares of Vertex Pharmaceuticals by 68.0% during the second quarter. Achmea Investment Management B.V. now owns 8,668 shares of the pharmaceutical company’s stock valued at $1,116,000 after buying an additional 3,507 shares during the last quarter. Picton Mahoney Asset Management acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $13,077,000. IFM Investors Pty Ltd acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $1,064,000. Janus Henderson Group PLC raised its position in shares of Vertex Pharmaceuticals by 1,191.3% during the second quarter. Janus Henderson Group PLC now owns 448,975 shares of the pharmaceutical company’s stock valued at $57,860,000 after buying an additional 414,206 shares during the last quarter. Finally, Icon Advisers Inc. Co. raised its position in shares of Vertex Pharmaceuticals by 93.1% during the third quarter. Icon Advisers Inc. Co. now owns 54,463 shares of the pharmaceutical company’s stock valued at $8,281,000 after buying an additional 26,253 shares during the last quarter. 93.14% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/28/vertex-pharmaceuticals-vrtx-upgraded-to-sell-at-bidaskclub.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply